More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease‑associated nephrotic syndrome following treatment with vincristine, adriamycin and high‑dose dexamethasone (VAD)

Czech version

Authors: Z. Adam ¹; M. Nedbálková ²; M. Krejčí ¹; L. Pour ¹; K. Hušek ³; K. Veselý ⁴; Z. Čermáková ⁵; A. Křivanová ¹; J. Mayer ¹; R. Hájek ¹
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc. 2II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MU Dr. Miroslav Souček, CSc. 3Ústav patologie L ¹
Published in: Vnitř Lék 2010; 56(3): 240-246
Category: Case Reports

Overview

Light chain deposits in the form of amorphous material (light chain deposition disease) damage most frequently kidneys and, less frequently, they affect other organs. The incidence of light chain deposition disease is much lower than that of AL‑ amyloidosis. Symmetrical swelling of both legs, swelling of the eye lids, erythrocyturia and nephrotic proteinuria were the first signs of light chain deposition disease in our patient. The disease was diagnosed from kidney biopsy performed at the stage of advanced nephrotic syndrome with reduced filtration. The bone marrow aspirate contained 0.8% of plasma cells, serum contained monoclonal immunoglobulin IgG‑ κ and urine contained free κ chains. Blood count was normal and no osteolytic changes to the skeleton were identified. The patient was, therefore, diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and was treated with 10 cycles of chemotherapy consisting of vincristine, adriamycin and high/ dose dexamethasone (VAD). Following the 10th cycle, the concentration of monoclonal IgG declined below the threshold for quantitative densitometric identification, while the more sensitive immunofixation electrophoresis remained positive. However, 2 months after the completion of chemotherapy, the immunofixation electrophoresis had become negative and thus complete haematological treatment response (remission) was achieved. Restoration of the kidney function was only gradual. Proteinuria declined below 1 g/ l and no erythrocyturia was present 4 years post‑treatment. Proteinuria declined to 0.19 g/ l, i.e. normal values, 9 years post‑treatment completion. Regular follow‑ups in patients with MGUS should seek to identify not only whether MGUS is transforming into malignant disease but also whether monoclonal immunoglobulin is damaging the organism. Treatment of patients with monoclonal immunoglobulin‑associated damage should be initiated early as the restoration of the affected organs function (organ treatment response) after complete haematological remission is only gradual. At present, treatment regimes with high‑dose dexamethasone are recommended for patients with primary systemic AL‑ amyloidosis. We believe that the same approach is suitable for the treatment of light chain deposition disease in MGUS patients.

Key words:
light chain deposition disease – monoclonal gammopathy of undetermined significance (MGUS) – multiple myeloma – renal insuficiency – nephrotic syndrome – AL‑ amyloidosis

Sources

1. Randall RE, Williamson WC Jr, Mullinax F et al. Manifestation of systemic light chain deposition. Am J Med 1976; 60: 293– 299.

2. Heilman RL, Velosa JA, Holley KE et al. Long term follow up and response to chemotherapy in patients with light chain deposition disease. Am J Kidney Dis 1992; 20: 34– 41.

3. Pozzi C, Fogazzi GB, Banfi G et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281– 287.

4. Wohl P, Chadimová M, Englis M et al. Light chain deposition disease as a cause of renal failure. Čas Lék Čes 1998; 137: 721– 724.

5. Zhu L, Herrera GA, Murphy‑ Ullrich JE et al. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor‑beta. Am J Pathol 1995; 147: 375– 385.

6. Bedossa P, Fabre M, Paraf F et al. Light chain deposition disease with liver dysfunction. Hum Pathol 1988; 19: 1008– 1014.

7. Girelli CM. Kappa light chain deposition of the liver. Eur J Gastroenterol Hepatol 1998; 10: 429– 430.

8. Pelletier G, Fabre M, Attali P et al. Light chain deposition disease presenting with hepatomegaly: an association with amyloid‑like fibrils. Postgrad Med J 1988; 64: 804– 808.

9. Kijner CH, Yousem SA. Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol 1988; 12: 405– 413.

10. Bhargava P, Rushin JM, Rusnock EJ et al. Pulmonary light chain deposition disease. Report of five cases and review of literature. Am J Surg Pathol 2007; 31: 267– 276.

11. Samanez C, Domingo A, Ciberia MT. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol 2006; 76: 83– 85.

12. Lambotte O, Dürrbach A, Ammor M et al. Association of a POEMS syndrome and light chain deposit disease: first case report. Clin Nephrol 2001; 55: 482– 486.

13. Merta M, Rysavá R, Zabka J et al. Kidney involvement in light‑chain deposition disease. Sb Lek 2002; 103: 397– 403.

14. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482– 1492.

15. Preud’homme JL, Aucouturier P, Tou-chard G et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46: 965– 972.

16. Venkataseshan VS, Faraggiana T, Hughson MD et al. Morphologic variants of light‑chain deposition disease in the kidney. Am J Nephrol 1988; 8: 272– 279.

17. Salant DJ, Sanchorawala V, D’Agati VD. A case of atypical light chain deposition disease – diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2: 858– 867.

18. Baur A, Stäbler A, Lamerz R et al. Light chain deposition disease in multiple myeloma: MR imaging features correlated with histopathological findings. Skeletal Radiol 1998; 27: 173– 176.

19. Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: light chain deposition disease. J Nephrol 2005; 18: 499– 502.

20. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light‑chain deposition disease. Ultrastruct Pathol 2008; 32: 17– 24.

21. Joh K. Pathology of glomerular deposition diseases. Pathol Int 2007; 57: 551– 565.

22. Gu X, Herrera AG. Light chain mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130: 165– 169.

23. Hofmann‑Guilaine C, Nochy D, Jacquot C et al. Association light chain deposition disease (LCDD) and amyloidosis. One case. Pathol Res Pract 1985; 180: 214– 219.

24. Jacquot C, Saint‑ Andre JP, Touchard G et al. Association of systemic light‑chain deposition disease and amyloidosis: a report of three patients with renal involvement. Clin Nephrol 1985; 24: 93– 98.

25. Okura T, Miyoshi K, Nagao T et al. Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Intern Med 2009; 48: 101– 104.

26. Pozzi C, D’Amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factor. Am J Kidney Dis 2003; 42: 1154– 1163.

27. Barraclough KA, Dowling JP, Schwarer AP et al. Sequential autologous peripheral blood stem cell transplantation and kidney transplantation of light chain deposition disease. Nephrol Dial Transplant 2007; 22: 1268– 1269.

28. Firkin F, Hill PA, Dwyer K et al. Reversal of dialysis dependent renal failure in light chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis 2004; 44: 551– 555.

29. Hassoun H, Flombaum C, D’Agati VD et al. High‑dose melphalan and auto‑ SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405– 412.

30. Pineda‑ Roman M, Tricot G. High‑dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 2007; 153: 182– 194.

31. Royer B, Arnulf B, Martinez F et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642– 648.

32. Sakakima M, Fujigaki Y, Tsuji T et al. High dose chemotherapy and stem cell support in a patient of light‑ and heavy‑chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med 2005; 44: 970– 974.

33. Wahner‑ Roedler DL, Kyle R. Heavy chain disease. Best Pract Res Clin Haematol 2005; 18: 729– 746.

34. Leung N, Lager DJ, Gertz MA et al. Long‑term outcome of renal transplantation in light‑chain deposition disease. Am J Kidney Dis 2004; 43: 147– 153.

35. Leung N, Slezak JM, Bergstralh EJ. Acute renal insufficiency after high dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 2005; 45: 102– 111.

36. Ganeval D, Noël LH, Preud’homme JL et al. Light chain deposition disease: Its relation with AL type amyloidosis. Kidney Int 1984; 26: 1– 9.

37. Gertz MA, Lacy MQ, Lust JA et al. Phase II trial of high‑dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999; 16: 104– 109.

38. Dhodapar MV, Hussein MA, Rasmussen E et al. Clinical efficacy of high dose dexamethasone wit maintenance dexamethasone/ interferon alpha in patients with primary systemic amyloidosis. Blood 2004; 104: 3520– 3526.

39. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high dose dexamethasone is effective and well tolerated in patients with AL‑ amyloidosis, who are ineligible for stem cell transplantation. Blood 2004; 103: 2936– 2938.

40. Palladini G, Russso P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long term remission in AL‑ amyloidosis. Blood 2007; 110: 787– 788.

41. Jaccard A, Moreau P, Leblond V et al. Autologous stem cell transplantation versus oral melphalan and high dose dexametasone in patients with primary AL‑ amyloidos. Randomized trial. Blood 2005; 106: 421.

42. Gerz MA, Lacy MQ, Lust JA et al. Phase II trial of high dose dexamethasone for previously treated immunoglobulin light‑chain amyloidosis. Am J Hematol 1999; 61: 115– 119.

43. Röcken C, Ernst J, Hund E et al. Interdisciplinary guidelines on the diagnosis of and therapy for systemic amyloidosis. Dtsch Med Wochenschr 2006; 131 (27 Suppl 2): S45– S66.

44. Comezo RL. Managing systemic light chain amyloidosis. J Natl Compr Canc Netw 2007; 5: 179– 187.

45. Lorenz EC, Gertz MA, Fervenza FC et al. Long‑term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052– 2057.

46. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL‑ amyloidosis. Swiss Med Wkly 2006; 136: 715– 720.

47. Brockhurst I, Harris KP, Chapman CS. Diagnosis and monitoring a case of light‑chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrol Dial Transplant 2005; 20: 1251– 1253.

48. Ščudla V, Minařík J, Schneiderka P et al. Význam sérových hladin volných lehkých řetězců imunoglobulinu v diagnostice a hodnocení aktivity mnohočetného myelomu a vybraných monoklonálních gamapatií. Vnitř Lék 2005; 51: 1249– 1259.

49. Tichý M, Hrnčíř Z, Urban P et al. Monoklonální imunoglobuliny. Klin Biochem Metabol 2004; 12: 84– 87.

50. Doubek M, Brychtova Y, Tomiska M et al. Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. Acta Haematol 2005; 113: 150– 151.

51. Tichý M, Urban P, Matěja P et al. Laboratorní analýza souboru 3049 monoklonálních imunoglobulinů. Klin Biochem Metabol 2002; 10: 257– 261.

52. Tichý M. Laboratorní analýza monoklonálních imunoglobulinů (paraproteinů). Český Těšín: Finidr 1997.